Doribax

Janssen-Cilag has launched Doribax (doripenem) for the treatment of nosocomial pneumonia (including ventilator-associated pneumonia), complicated intra-abdominal and urinary tract infections.

Doripenem is a carbapenem with a broad spectrum of activity. It inhibits bacterial cell wall biosynthesis and is indicated for the treatment of serious infections in secondary care.

Doripenem is given by infusion over one to four hours every eight hours. The longer infusion period should be considered when the infection is caused by less susceptible pathogens; extending the infusion time maximises the period when the plasma concentration exceeds the minimum inhibitory concentration.

Species resistant to other carbapenems do generally express co-resistance to doripenem.

View Doribax drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

'Innovative' heart failure treatment recommended by NICE

'Innovative' heart failure treatment recommended by NICE

Dapagliflozin (Forxiga), the first SGLT2 inhibitor...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregabalin linked to severe respiratory depression in absence of opioids

Pregabalin linked to severe respiratory depression in absence of opioids

The MHRA advises prescribers to consider adjustment...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...